Similar articles

• Stroke prevention: antiplatelet and antithrombolytic therapy.

  Diener HC. Diener HC. Haemostasis. 2000;30 Suppl 3:14-26. doi: 10.1159/000054194. Haemostasis. 2000. PMID: 11182625 Review. No abstract available.
• MATCH results: implications for the internist.

  Lutsep HL. Lutsep HL. Am J Med. 2006 Jun;119(6):526.e1-7. doi: 10.1016/j.amjmed.2005.10.047. Am J Med. 2006. PMID: 16750967 Review.
• Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.

  [No authors listed] [No authors listed] Cardiovasc J Afr. 2008 May-Jun;19(3):165. Cardiovasc J Afr. 2008. PMID: 18568182 No abstract available.
• Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.

  Serebruany VL, Malinin AI, Pokov AN, Hanley DF. Serebruany VL, et al. Clin Ther. 2008 Feb;30(2):249-59. doi: 10.1016/j.clinthera.2008.02.006. Clin Ther. 2008. PMID: 18343263 Clinical Trial.
• Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.

  Warlow C. Warlow C. Stroke. 2002 Aug;33(8):2137-8. doi: 10.1161/01.str.0000023120.91460.f3. Stroke. 2002. PMID: 12154276 No abstract available.